Bladder Cancer

A phase 2 study of neoadjuvant gemcitabine, cisplatin, plus nivolumab met its co-primary end point with a positive predictive value of clinical complete response of 0.97 among patients with muscle-invasive bladder cancer.

Over three-fourths of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer treated with TAR-200 achieved complete responses in the phase 2b SUNRISE-1 trial.

Enfortumab vedotin-ejfv plus pembrolizumab improves survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

The addition of nivolumab to frontline standard of care gemcitabine-cisplatin, followed by nivolumab maintenance therapy, led to statistically significant and clinically meaningful improvements in survival compared with gemcitabine-cisplatin alone in patients with unresectable or metastatic urothelial carcinoma.

A post hoc analysis of overall survival and progression-free survival support the use of avelumab with best supportive care as a standard of care for patients with urothelial carcinoma.

Findings from the CheckMate-901 trial demonstrated improvements for the treatment of patients with urothelial carcinoma who received a combination of nivolumab and chemotherapy followed by nivolumab monotherapy.

Meeting a primary end point, KEYNOTE-123 study shows promise for pembrolizumab as an adjuvant muscle-invasive bladder cancer treatment.

The ADVANCED-2 trial plans to build onto the early antitumor and safety data seen with TARA-002 that were presented this year for patients with non-muscle invasive bladder cancer.

Seagen Inc., and Astellas Pharma Inc., report that both primary end points of the phase 3 EV-302 clinical trial have been met.

In an interview with Targeted Oncology, Arlene O. Siefker-Radtke, MD, discusses the findings from 3 trials of erdafitinib and explains the next steps for evaluating the agent.

Nadofaragene firadenovec-vncg received FDA approval for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer in 2022, and is now being evaluated further in the ABLE-41 trial.

Promising overall survival findings from cohort 1 of the THOR study evaluating erdafitinib in locally advanced or metastatic urothelial cancer have pushed the agent’s developer to submit an sNDA seeking its full approval.

A single-arm trial induced high event-free and overall survival with the addition of durvalumab to standard of care before radical surgery in patients with muscle-invasive urothelial carcinoma.

In an interview with Targeted Oncology, Daniel P. Petrylak, MD, discussed findings from the TROPHY-U-01 study for patients with mUC, and what the next steps for research are.

In an interview, Shilpa Gupta, MD, discussed findings from cohort A of Study EV-103 in patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

Topline data from the phase 3 ATLAS and ENVISION trials of UGN-102 showed a robust and consistent therapeutic profile when used for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

A total of 110 patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer have been enrolled in a phase 3 study evaluating cretostimogene grenadenorepvec.

In an interview, Rohan Garje, MD, discussed his research on comparing the outcomes of sarcomatoid and classic urothelial carcinoma of bladder.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed when in sequence they would use sacituzumab govitecan for patients with metastatic urothelial cancer. This is the second of 2 articles based on this event.

Discussing findings from a phase 1/2 study, Sarah P. Psutka MD, looks at the use of acupuncture for patients with non muscle-invasive bladder cancer prior to induction of their BCG treatment.

A further look at nivolumab combined with cisplatin-based chemotherapy outside of the primary CheckMate-901 study shows survival benefit for the study combination.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, discussed data supporting the use of sacituzumab govitecan in advanced urothelial carcinoma.

For Bladder Cancer Awareness Month, Jahan Aghalar, MD, discussed the latest advancements in treating patients with bladder cancer along with which targets have helped to push the field forward.

In an interview with Targeted Oncology, Siamak Daneshmand, MD, discussed TAR-200 as seen in the SunRISE-1 trial and the what is up next for the treatment landscape of high-risk BCG-unresponsive non-muscle invasive bladder cancer.

In an interview with Targeted Oncology, Petros Grivas, MD, PhD, discusses the set up and key results from the KEYNOTE-057 trial of pembrolizumab for patients with bacillus Calmette-Guérin-unresponsive, papillary high-risk non–muscle-invasive bladder cancer.

FDA approval has not been granted to N-803 for the treatment of Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ.

Emerging data demonstrate the potential of these drugs to optimize survival, preserve quality of life, and even spare patients a radical cystectomy.

Treatment with TARA-002 at 3 different dose levels was generally well-tolerated, and no dose limiting toxicities were observed among patients with high-grade non-muscle invasive bladder cancer.

At the 2023 National Comprehensive Cancer Network Annual Conference, Arlene O. Siefker-Radtke, MD, gave an assessment on where emerging targeted therapies for patients with metastatic or advanced bladder stand.

Enfortumab vedotin plus pembrolizumab is now an FDA approved treatment based on positive phase 1b/2 findings.